Literature DB >> 19804470

Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate.

T Terada1, Y Tsuboi, T Obi, K Doh-ura, S Murayama, T Kitamoto, T Yamada, K Mizoguchi.   

Abstract

Treatment with intraventricular pentosan polysulphate (PPS) might be beneficial in patients with Creutzfeldt-Jakob disease. We report a 68-year-old woman with sporadic Creutzfeldt-Jakob disease who received continuous intraventricular PPS infusion (1-120 microg/kg/day) for 17 months starting 10 months after the onset of clinical symptoms. Treatment with PPS was well tolerated but was associated with a minor, transient intraventricular hemorrhage and a non-progressive collection of subdural fluid. The patient's overall survival time was well above the mean time expected for the illness but still within the normal range. Post-mortem examination revealed that the level of abnormal protease-resistant prion protein in the brain was markedly decreased compared with levels in brains without PPS treatment. These findings suggest that intraventricular PPS infusion might modify the accumulation of abnormal prion proteins in the brains of patients with sporadic Creutzfeldt-Jakob disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804470     DOI: 10.1111/j.1600-0404.2009.01272.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  13 in total

Review 1.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

Review 2.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

3.  Polythiophenes inhibit prion propagation by stabilizing prion protein (PrP) aggregates.

Authors:  Ilan Margalith; Carlo Suter; Boris Ballmer; Petra Schwarz; Cinzia Tiberi; Tiziana Sonati; Jeppe Falsig; Sofie Nyström; Per Hammarström; Andreas Aslund; K Peter R Nilsson; Alice Yam; Eric Whitters; Simone Hornemann; Adriano Aguzzi
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

Review 4.  Therapeutic development of polymers for prion disease.

Authors:  Kenta Teruya; Katsumi Doh-Ura
Journal:  Cell Tissue Res       Date:  2022-03-21       Impact factor: 5.249

5.  Unfolded and intermediate states of PrP play a key role in the mechanism of action of an antiprion chaperone.

Authors:  Rafayel Petrosyan; Shubhadeep Patra; Negar Rezajooei; Craig R Garen; Michael T Woodside
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 6.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

7.  Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Dennisse Gonzalez-Romero; Kristi Green; Giulio Taglialatela; Claudio Soto
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

8.  Heparin binding confers prion stability and impairs its aggregation.

Authors:  Tuane C R G Vieira; Yraima Cordeiro; Byron Caughey; Jerson L Silva
Journal:  FASEB J       Date:  2014-03-19       Impact factor: 5.191

9.  Sulfated dextrans enhance in vitro amplification of bovine spongiform encephalopathy PrP(Sc) and enable ultrasensitive detection of bovine PrP(Sc).

Authors:  Yuichi Murayama; Miyako Yoshioka; Kentaro Masujin; Hiroyuki Okada; Yoshifumi Iwamaru; Morikazu Imamura; Yuichi Matsuura; Shigeo Fukuda; Sadao Onoe; Takashi Yokoyama; Shirou Mohri
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

Review 10.  The role of prion strain diversity in the development of successful therapeutic treatments.

Authors:  Sara A M Holec; Alyssa J Block; Jason C Bartz
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-28       Impact factor: 3.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.